Cytokinetics Inc (NASDAQ:CYTK)’s traded shares stood at 2.99 million during the latest session, with the company’s beta value hitting 0.73. At the last check today, the stock’s price was $35.35, to imply a decrease of -17.65% or -$7.57 in intraday trading. The CYTK share’s 52-week high remains $68.44, putting it -93.61% down since that peak but still an impressive 7.38% since price per share fell to its 52-week low of $32.74. The company has a valuation of $4.21B, with an average of 1.4 million shares in intraday trading volume over the past 10 days and average of 1.99 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cytokinetics Inc (CYTK), translating to a mean rating of 1.35. Of 12 analyst(s) looking at the stock, 0 analyst(s) give CYTK a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 11 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -1.36.
Cytokinetics Inc (NASDAQ:CYTK) trade information
After registering a -17.65% downside in the latest session, Cytokinetics Inc (CYTK) has traded red over the past five days. The 5-day price performance for the stock is -12.58%, and -12.19% over 30 days. With these gigs, the year-to-date price performance is -24.86%. Short interest in Cytokinetics Inc (NASDAQ:CYTK) saw shorts transact 13.95 million shares and set a 5.85 days time to cover.
The extremes give us $55 and $67 for target low and target high price respectively. As such, CYTK has been trading -89.53% off suggested target high and -55.59% from its likely low.
Cytokinetics Inc (CYTK) estimates and forecasts
The rating firms project that company’s revenue will grow 85.20% compared to the previous financial year.
Revenue forecast for the current quarter as set by 16 analysts is 2.77M. Meanwhile, for the current quarter, a total of 16 analyst(s) estimate revenue growth to 2.96M.Earnings reports from the last fiscal year show that sales brought in 835k and 249k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 232.15% before jumping 1,089.48% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -20.02% for the past 5-year period. While 2025 is set for a -8.90% return in earnings, projections for the next 5 years are at 17.92% annually.
CYTK Dividends
Cytokinetics Inc has its next earnings report out on 2025-Feb-26. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Cytokinetics Inc (NASDAQ:CYTK)’s Major holders
Cytokinetics Inc insiders hold 0.71% of total outstanding shares, with institutional holders owning 114.49% of the shares at 115.31% float percentage. In total, 114.49% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 14.67 million shares (or 13.4317% of shares), all amounting to roughly $794.97 million.
The next major institution holding the largest number of shares is FMR LLC with 11.52 million shares, or about 10.5485% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $624.32 million.
We also have VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and iShares Trust-iShares Core S&P Mid-Cap ETF as the top two Mutual Funds with the largest holdings of the Cytokinetics Inc (CYTK) shares. Going by data provided on Jan 31, 2025 , VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund holds roughly 4.07 shares. This is just over 3.41% of the total shares, with a market valuation of $145.86 million. Data from the same date shows that the other fund manager holds a little less at 3.85, or 3.23% of the shares, all valued at about 138.22 million.
